NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Kura Oncology, Inc.
Janssen Research & Development, LLC
Servier
Daiichi Sankyo
Astellas Pharma Inc
Lumos Pharma
Hoffmann-La Roche